CNTX
|Context Therapeutics Inc
NASDAQ
USD 0.56
-0.01|-2.34%
Current Price
USD 0.56
Change
USD -0.01 (-2.34%)
P/E Ratio
Dividend Yield
Market Cap
51.61M
Volume
171,126
Open
USD 0.60
Previous Close
USD 0.58
52-Week High
USD 2.75
52-Week Low
USD 0.49
About Context Therapeutics Inc
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Martin A. Lehr
Employees:12
Headquarters:Philadelphia, USA
Website:www.contexttherapeutics.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions